X4 Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule modulators of G protein-coupled receptors (GPCRs). The company’s research emphasizes the SDF-1/CXCR4 axis and other GPCR targets to regulate cell trafficking and immune response. X4’s technology platform is designed to address unmet needs in oncology, immunology and rare diseases by selectively modulating receptor activity.
The lead candidate in X4’s pipeline, X4P-001, is being developed as a therapeutic agent to mobilize hematopoietic stem cells for transplantation and to enhance immune-oncology regimens. Additional programs include X4P-202, a selective sphingosine-1-phosphate receptor modulator with potential applications in pulmonary arterial hypertension and autoimmune disorders, and X4P-003, targeting rare immunological diseases. These programs are advancing through preclinical and early clinical stages with a goal of demonstrating safety and efficacy in well‐defined patient populations.
Founded as a spin-out from GlycoMimetics in 2020 and headquartered in Cambridge, Massachusetts, X4 Pharmaceuticals leverages both in‐house expertise and external collaborations to accelerate development. The company maintains research activities in the United States and Europe and has established partnerships with academic institutions and contract research organizations to support its preclinical and clinical efforts.
Under the leadership of President and Chief Executive Officer Monee C. McGrath, X4 Pharmaceuticals has assembled a management team with deep experience in drug discovery, clinical development and regulatory affairs. The company’s strategic focus on novel GPCR modulators positions it to deliver differentiated therapies aimed at improving outcomes for patients with serious and underserved diseases.
AI Generated. May Contain Errors.
